Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG958

—

d08ed69f-151d-5ed7-a4d6-afd0e343d222

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.453
  • UNFOLDED_PROTEIN_RESPONSE+0.403
  • IL6_JAK_STAT3_SIGNALING+0.338
  • ADIPOGENESIS+0.326
  • INTERFERON_ALPHA_RESPONSE+0.297
  • TGF_BETA_SIGNALING+0.294
  • MYC_TARGETS_V1+0.279
  • PI3K_AKT_MTOR_SIGNALING+0.279
  • UV_RESPONSE_DN+0.274
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.268

Top 10 suppressed

  • APICAL_SURFACE-0.385
  • E2F_TARGETS-0.336
  • TNFA_SIGNALING_VIA_NFKB-0.311
  • CHOLESTEROL_HOMEOSTASIS-0.277
  • G2M_CHECKPOINT-0.269
  • KRAS_SIGNALING_DN-0.185
  • ANGIOGENESIS-0.161
  • PANCREAS_BETA_CELLS-0.133
  • HYPOXIA-0.132
  • ESTROGEN_RESPONSE_LATE-0.124

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1218
mng-umap@100
——0.802
2MNG240
mng-umap@100
——0.748
3MNG1046
mng-umap@100
——0.734
4DRR168542
bladder-landscape@3
——0.718
5MNG1167
mng-umap@100
——0.718
6MNG1276
mng-umap@100
——0.711
7MNG765
mng-umap@100
——0.711
8MNG1031
mng-umap@100
——0.689
9MNG781
mng-umap@100
——0.684
10MNG632
mng-umap@100
——0.677

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.453Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.403Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.338Inavolisib— uncovered
ADIPOGENESIS0.326Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.297Inavolisib— uncovered
TGF_BETA_SIGNALING0.294Inavolisib— uncovered
MYC_TARGETS_V10.279Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.279Inavolisib— uncovered
UV_RESPONSE_DN0.274Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.268Inavolisib— uncovered
PROTEIN_SECRETION0.259Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.227Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.211Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.185Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.169Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.169Inavolisib— uncovered
MTORC1_SIGNALING0.167Inavolisib— uncovered
DNA_REPAIR0.159Idelalisib— uncovered
HEME_METABOLISM0.140Temsirolimus— uncovered
UV_RESPONSE_UP0.138Idelalisib— uncovered